Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft synthesis: Dependence of reported purity on the… — submissions

The 4 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-119/2
Series
Public comment period
Version
1.0
Published
19 Jul 2026
Last reviewed
19 Jul 2026
Next review
19 Jul 2027
Identifier
10.71829/cei.cp.119
Certainty
Not rated
Cycle
2026 Q3
Window
19 Jul 2026 – 30 Aug 2026
Status
Open
Submissions
4

§2Submissions and responses

4 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Eamon Sandringham-Adu, MSc (Clinical Pharmacy) Regional hospital pharmacy department · submitting on medicines information
DRAFT-PEPTIDE-PURI/001 received 01 Aug 2026

The review protocol is described but its registration record is not linked

The draft review of How much does a reported chromatographic purity figure vary with the method used to obtain it? was read against the certificates and reports it draws on.

The respondent asks for the prospective registration record of the review protocol so that the registered outcomes can be compared with the reported ones.

The respondent states that without it the claim of prospective registration cannot be checked.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted in part25 Sep 2026

The secretariat accepts this submission in part. The protocol is published in full on the Institute site with its version history, which permits the comparison the respondent asks for. Where an external registration identifier is not held by the Institute, the review says so rather than supplying one.

Each synthesis now links its own protocol with the version in force at screening, and states explicitly where an external registration identifier is not held, so that the absence is a recorded fact.

Dr Anselm Thorsby-Nakamura, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-PEPTIDE-PURI/002 received 03 Aug 2026

Results obtained by different methods are pooled without recording the method

The respondent has read the draft synthesis on How much does a reported chromatographic purity figure vary with the method used to obtain it? and makes one submission about the analytical evidence it pools.

The contributing results were obtained by more than one determination, and the draft reports a single distribution.

The respondent states that the determinations do not measure the same quantity, that the difference between them is systematic rather than random, and that a pooled distribution across methods has no referent.

The respondent proposes that every result carry the method that produced it and that pooling occur only within a method.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted27 Sep 2026

The secretariat accepts this submission. A figure whose method is not recorded cannot be compared with another figure, and the draft pooled across the difference.

Every contributing result now carries its determination, pooling occurs only within a determination, and where a survey did not report the method the result is listed as method not stated and excluded from the pooled estimates.

Thaddeus Isaksen-Balogun, MSc (Epidemiology) Academic biostatistics group · submitting on biostatistics
DRAFT-PEPTIDE-PURI/003 received 05 Aug 2026

Multiple vials from one lot are counted as independent observations

The respondent notes that the review question — How much does a reported chromatographic purity figure vary with the method used to obtain it? — is answerable only if the contributing determinations measured the same quantity, and submits with that in view.

Several contributing surveys report results for more than one vial drawn from a single lot, and the draft counts each vial as a separate observation.

The respondent states that vials from one lot share a fill and a manufacturing history, so the effective number of independent observations is the number of lots and not the number of vials, and that the interval reported is narrower than the data support.

The respondent proposes that the unit of analysis be the lot, with within-lot variation reported separately.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted in part12 Sep 2026

The secretariat accepts the unit-of-analysis point and declines to discard the within-lot data, which are informative about fill uniformity.

The unit of analysis is now the lot throughout, the number of lots is reported beside the number of vials, and within-lot variation is reported as a separate quantity rather than folded into the pooled interval.

Professor Bartolomeu Nkosi-Lindegaard, PhD Professor of Regulatory Science · submitting on regulatory science
DRAFT-PEPTIDE-PURI/004 received 10 Aug 2026

Regulatory assessment documents were not searched

The respondent’s comment on the draft review of How much does a reported chromatographic purity figure vary with the method used to obtain it? arises from comparing the pooled figures against the reports they were taken from.

The respondent states that regulatory assessment reports frequently contain analyses that never appear in journals, and that a search limited to bibliographic databases will miss them.

The respondent proposes that regulatory documents be searched for every review in the series.

The respondent has read submission 002 with interest and adds one observation the secretariat may find useful.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted in part20 Sep 2026

The secretariat accepts this submission in part. Regulatory assessment documents are searched. The proposal that they be treated as equivalent to a full study report is declined, because the level of detail varies and is often insufficient for risk-of-bias assessment.

Published regulatory assessment documents are now searched as a named source, are reported as a distinct evidence class in the included-studies table, and contribute to the assessment while being excluded from pooled estimates where risk of bias could not be assessed from the document.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.